English
French
Press Release
|
18 |
Dec 2023 |
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®... |
|
05 |
Dec 2023 |
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences fo... |
|
04 |
Dec 2023 |
IntelGenx Announces Changes to its Board of Directors... |
|
28 |
Nov 2023 |
IntelGenx Announces Shareholder Approval of Financing Transactions... |
|
14 |
Nov 2023 |
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Pa... |
|
13 |
Nov 2023 |
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting... |
|
09 |
Nov 2023 |
IntelGenx Reports Third Quarter 2023 Financial Results... |
|
06 |
Nov 2023 |
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray... |
|
02 |
Nov 2023 |
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow... |
|
21 |
Sep 2023 |
IntelGenx Provides RIZAFILM® U.S. Commercialization Update... |
|
19 |
Sep 2023 |
IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film... |
|
31 |
Aug 2023 |
IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Ag... |
|
14 |
Aug 2023 |
IntelGenx Reports Second Quarter 2023 Financial Results... |
|
10 |
Aug 2023 |
IntelGenx Announces First Agreement for CDMO Packaging Services... |
|
07 |
Aug 2023 |
IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow... |
|
01 |
Aug 2023 |
IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to ... |
|
25 |
Jul 2023 |
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’... |
|
21 |
Jul 2023 |
IntelGenx Announces a Change to its Board of Directors... |
|
06 |
Jul 2023 |
IntelGenx Announces Voting Results on Election of Directors... |
|
31 |
May 2023 |
IntelGenx Unveils Short-Term Commercial Objectives... |
|
17 |
May 2023 |
IntelGenx Receives Amended DEL License to Conduct Third-Party Testing... |
|
11 |
May 2023 |
IntelGenx Reports First Quarter 2023 Financial Results... |
|
04 |
May 2023 |
IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow... |
|
27 |
Apr 2023 |
IntelGenx Extends Period to Exercise Certain Warrants... |
|
27 |
Apr 2023 |
IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film... |
|
17 |
Apr 2023 |
IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine... |
|
13 |
Apr 2023 |
IntelGenx Announces Organizational Changes to Support Global Growth Strategy... |
|
29 |
Mar 2023 |
IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results... |
|
24 |
Mar 2023 |
IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 20... |
|
23 |
Mar 2023 |
IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow... |
|
21 |
Mar 2023 |
IntelGenx Announces Closing of Notes Offering... |
|
09 |
Mar 2023 |
IntelGenx to Participate in the 35th Annual Roth Conference... |
|
21 |
Feb 2023 |
IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent... |
|
09 |
Feb 2023 |
IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatme... |
|
23 |
Jan 2023 |
IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries... |
|
09 |
Jan 2023 |
IntelGenx Receives Fourth and Final Loan Tranche from atai... |